Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564408 | 0.78 | CA2 (0.43) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL3957389 | 0.76 | CA2 (0.42) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL28087904 | 0.76 | CA2 (0.42) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL29609286 | 0.76 | CA2 (0.42) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL15397878 | 0.76 | CA2 (0.42) | CA2CA4CA5ACFTRALDH1A1 | |
| Hydrochloric Acid SCHEMBL10713177 | 0.74 | CA2 (0.40) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL6327852 | 0.71 | CA2 (0.41) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL10712482 | 0.70 | CA2 (0.37) | CA2CA4CA5ACFTRALDH1A1 | |
| Acetic Acid SCHEMBL19208997 | 0.69 | KMT2A (0.41) | CA2CA4CA5ACFTRALDH1A1 | |
| SCHEMBL9466535 | 0.67 | MIF (0.43) | CA2CA4CA5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220115694-A1 | LITHIUM ION BATTERIES WITH HIGH VOLTAGE ELECTROLYTE ADDITIVES | WILDCAT DISCOVERY TECHNOLOGIES, INC | 2022-04-14 | — | — | US | claimed |
| EP-4647427-A1 | COMPOUND FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASE | TYK Medicines, Inc. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | disclosed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | disclosed |
| US-20220115694-A1 | LITHIUM ION BATTERIES WITH HIGH VOLTAGE ELECTROLYTE ADDITIVES | WILDCAT DISCOVERY TECHNOLOGIES, INC | 2022-04-14 | — | — | US | disclosed |
| EP-3699174-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2020-08-26 | — | — | EP | disclosed |
| US-20200246304-A1 | Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same | ILAB (KR) | 2020-08-06 | — | — | US | disclosed |
| US-20190217268-A1 | CHEMICAL REACTION DEVICE, AND METHOD FOR PRODUCING SAME | NEC CORPORATION (JP) | 2019-07-18 | — | — | US | disclosed |
| US-10119972-B2 | Reactive labelling compounds and uses thereof | ACADEMIA SINICA (TW) | 2018-11-06 | — | — | US | disclosed |
| US-10011589-B2 | Treatments for gastrointestinal conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-07-03 | — | — | US | disclosed |
| EP-0866801-A1 | CYCLOPEPTOLIDES | Novartis AG (CH) | 1998-09-30 | — | — | EP | disclosed |
| EP-0793656-A1 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-09-10 | — | — | EP | disclosed |
| WO-1997019104-A1 | CYCLOPEPTOLIDES | NOVARTIS AG (CH) | 1997-05-29 | — | — | WO | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
| EP-0482100-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1992-04-29 | — | — | EP | disclosed |
| EP-0479871-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991000271-A1 | NOVEL VITAMIN D ANALOGUES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1991-01-10 | — | — | WO | disclosed |
| EP-0174858-A1 | Isoindolinone derivatives, production and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1986-03-19 | — | — | EP | disclosed |
| EP-0050534-A1 | Esters of cyclopropane-carboxylic acids related to pyrethric acid, their preparation and use as insecticides | ROUSSEL-UCLAF (FR) | 1982-04-28 | — | — | EP | disclosed |
| US-4324902-A | 7-[5-Oxo-3-hydroxy-2-(3-substituted)-3-hydroxypropyl)-1-cyclopentene]-heptanoic acids and derivatives thereof | G. D. SEARLE & CO. (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011589-B2 | Treatments for gastrointestinal conditions | SI, FABP2, SLC10A2 | CA2 681/4885CA4 445/4885CA5A 171/4885 |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | CA2 2558/4885CA4 2600/4885CA5A 4421/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | CA2 2558/4885CA4 2600/4885CA5A 4421/4885 |
| US-10119972-B2 | Reactive labelling compounds and uses thereof | MPI, AADAC, PAICS | CA2 3647/4885CA4 760/4885CA5A 309/4885 |
| US-20200246304-A1 | Composition For Preventing Or Treating TNF-Related Diseases, Containing Novel Derivative As Active Ingredient, And Method For Inhibiting TNF Activity By Using Same | TNF, NFKBIA, TRAF6 | CA2 2558/4885CA4 2600/4885CA5A 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.